Cover Image
市場調查報告書

全球核醫學放射性同位素市場 - 分析與預測(2017年∼2022年)

Global Nuclear Medicine Radioisotopes Market - Segmented by type of Radioisotopes, Application and Geography - Growth, Trend and Geography (2018 - 2023)

出版商 Mordor Intelligence LLP 商品編碼 353858
出版日期 內容資訊 英文 103 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球核醫學放射性同位素市場 - 分析與預測(2017年∼2022年) Global Nuclear Medicine Radioisotopes Market - Segmented by type of Radioisotopes, Application and Geography - Growth, Trend and Geography (2018 - 2023)
出版日期: 2018年02月08日 內容資訊: 英文 103 Pages
簡介

全球放射性同位素市場,2014年價值85億5000萬美元,預計至2019年將以12.45%的年複合成長率達到153億7000萬美元。

本報告提供全球核醫學放射性同位素市場相關調查,市場概要,各種類、應用領域、地區的市場趨勢,市場規模的變化與預測,市場成長、阻礙因素以及市場機會、課題分析,市場佔有率,競爭情形,主要企業的簡介等,全面性資訊。

目錄

第1章 簡介

  • 市場定義
  • 市場規模估計

第2章 調查方法

第3章 摘要整理

第4章 市場概要

  • 放射性醫藥品定義
  • 市場佔有率分析
  • 市場成長要素
    • 癌症及心臟疾病的發病率上升
    • 開發更佳的醫療設備
    • SPECT及PET的應用增加
    • 患者的關心增加
  • 市場阻礙因素
    • 嚴格的法規問題
  • 市場機會
    • 成像技術的成長
  • 神經學的應用的增加

第5章 市場區隔

  • 各類型
    • 鎝-99m(Tc-99m)
    • 鉈-201(Tl-201)
    • 碘(I-123)
    • 氟-18
    • 銣-82(Rb-82)
    • 碘-131(I-131)
    • 釔-90(Y-90)
    • 釤153(Sm-153)
    • 錸-186(Re-186)
    • 鎦-177(Lu-177)
    • 鐳223(Ra-223)及Alpharadin
    • 錒-225(Ac-225)
    • 鉛-212(Pb-212)/鉍-212(Bi-212)
    • 砈-211(At-211)
    • 鐳-224(Ra-224)
    • 釷-227(Th-227)
    • 銫131
    • 碘-125
    • 鈀-103
    • 銥-192
    • 其他
  • 各應用領域
    • 腫瘤
    • 心臟病
    • 淋巴瘤
    • 甲狀腺
    • 神經
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 其他地區

第6章 競爭情形

  • 收購與合併
  • 新產品的銷售
  • 協定與合作

第7章 公司簡介

  • AGFA-GEVAERT NV
  • CARDIARC LTD
  • DIGIRAD CORPORATION
  • GAMMA MEDICA INC
  • GE HEALTHCARE
  • HOLOGIC INC.
  • MEDX INC
  • NAVISCAN INC
  • POSITRON CORPORATION
  • SEGAMI CORPORATION
  • SIEMENS HEALTHCARE

第8章 附錄

  • 簡稱
  • 參考文獻
  • 免責聲明

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 19407

The global nuclear medicine radioisotopes market has been estimated to reach USD 13.9 billion in 2017.The market is expected to register a CAGR of 12.3% during the forecast period 2018 to 2023. North America accounted for the largest market share, for approximately 40% of the global market share in 2017, while Asia-Pacific region was estimated to register the fastest CAGR through the forecast period, 2018-2023.

Rising SPECT and PET Applications

The field of nuclear medicine is dominated by the applications related to positron emission tomography (PET) and single-photon emission computerized tomography (SPECT). Growing interest of PET technology in cardiac and neurological disorders is expected to fuel the market growth. More than 60% of SPECT procedures are performed in cardiology and in addition, orthopedics, oncology and infection imaging are emerging as areas that can benefit from the same. Applications are further increased through the inclusion of advancements in computed tomography (CT), making nuclear medicine as a rising choice for disease diagnosis. In addition, factors such as rising incidences of cardiac and cancer cases along-with rising awareness of public for the same, drives the nuclear medicine market.

High Capital Investments is involved

One of the major hindrance for the nuclear medicine radioisotopes market is the high capital investments required for the generation of radionuclide. Cyclotron initial investment is very high which followed by renovation and installation and further annual operating costs are involved. With high investment, the cost of imaging and treatment overall becomes a factor of high expenditure especially in developing markets. These factors including unclear regulatory guidelines and varied reimbursement policies and short half-life of radiopharmaceuticals restricts the growth of this market.

North America to Dominate this Market

The global nuclear medicine radioisotopes market is segmented by types of radioisotopes, by applications in different indications and geography. Geographically, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa and South America.

North America dominated the nuclear medicine radioisotopes market with approximately 40% of the global market share in 2017. The factors such as well-established healthcare facilities and the rise in geriatric population, with rising awareness among people for nuclear medicine treatments and diagnosis contribute to the growth of this market in the region. Moreover, Asia-Pacific region was estimated to register the fastest CAGR through the forecast period, 2018-2023.

Key Developments in the Market

December 2017: Caris Life Sciences identified a new mechanism for the treatment of non-Hodgkin lymphoma (NHL) using a single-stranded DNA aptamer, C10.36, specifically binding to heterogeneous nuclear ribonucleoprotein U (hnRNP U).

October 2017: Siemens Healthcare introduced biograph vision PET/CT system, a software platform at the 30th Annual Congress of the European Association of Nuclear Medicine (EANM), to provide a new level of precision in PET/CT imaging.

Major Players: MEDTRONIC plc, GE HEALTHCARE, LANTHEUS MEDICAL IMAGING inc, HOLOGIC inc, CARDINAL HEALTH inc, BAYER HEALTHCARE ag, BRACCO IMAGING spa, NTP RADIOISOTOPES SOC ltd, POSITRON CORPORATION and SIEMENS HEALTHCARE

Reasons to Purchase the Report

Market analysis for the Global Nuclear Medicine Radioisotopes Market, with region-specific assessments and competition analysis on a global and regional scale.

Analyzing various perspectives of the industry with the help of Porter's five forces analysis.

The treatment type that is expected to dominate the market.

Regions that are expected to witness fastest growth during the forecast period.

Identify the latest developments, market shares and strategies employed by the major market players.

3 months analyst support along with the Market Estimate sheet in excel.

Customization of the Report

This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs.

Table of Contents

1 Introduction

  • 1.1 Market Definition

2 Research Methodology

3 Executive Summary

4 Key Inferences

5 Market Overview

  • 5.1 Current Market Scenario
  • 5.2 Porters Five Forces
    • 5.2.1 Bargaining Power Of Suppliers
    • 5.2.2 Bargaining Power Of Consumers
    • 5.2.3 Threats Of New Entrants
    • 5.2.4 Threat Of Substitute Product And Services
    • 5.2.5 Competitive Rivalry Within The Industry

6 Drivers, Restraints, Opportunities And Challenges Analysis (Droc)

  • 6.1 Market Drivers
    • 6.1.1 Increasing Incidents Of Cancer And Cardiac Ailments
    • 6.1.2 Increasing Spect And Pet Applications
    • 6.1.3 Growing Public Awareness For Healthcare
  • 6.2 Market Constraints
    • 6.2.1 High Capital Investment
    • 6.2.2 Regulatory Guidelines
    • 6.2.3 Reimbursement Issues
  • 6.3 Opportunities
  • 6.4 Threats

7 Market Segmentation

  • 7.1 By Type Of Radioisotopes
    • 7.1.1 Technetium-99m (Tc-99m)
    • 7.1.2 Thallium-201 (Tl-201)
    • 7.1.3 Iodine (I-123)
    • 7.1.4 Fluorine-18
    • 7.1.5 Rubidium-82 (Rb-82)
    • 7.1.6 Iodine-131 (I-131)
    • 7.1.7 Yttrium-90 (Y-90)
    • 7.1.8 Samarium-153 (Sm-153)
    • 7.1.9 Rhenium-186 (Re-186)
    • 7.1.10 Lutetium-177 (Lu-177)
    • 7.1.11 Radium-223 (Ra-223) & Alpharadin
    • 7.1.12 Actinium-225 (Ac-225)
    • 7.1.13 Lead-212 (Pb-212)/Bismuth-212 (Bi-212)
    • 7.1.14 Astatine-211 (At-211)
    • 7.1.15 Radium-224 (Ra-224)
    • 7.1.16 Thorium-227 (Th-227)
    • 7.1.17 Cesium-131
    • 7.1.18 Iodine-125
    • 7.1.19 Palladium-103
    • 7.1.20 Iridium-192
    • 7.1.21 Others
  • 7.2 By Applications
    • 7.2.1 Oncology
    • 7.2.2 Cardiology
    • 7.2.3 Lymphoma
    • 7.2.4 Thyroid
    • 7.2.5 Neurology
    • 7.2.6 Others
  • 7.3 Segmentation By Geography
    • 7.3.1north America
      • 7.3.1.1 United States
      • 7.3.1.2 Canada
      • 7.3.1.3 Mexico
    • 7.3.2 Europe
      • 7.3.2.1 France
      • 7.3.2.2 Germany
      • 7.3.2.3 United Kingdom
      • 7.2.3.4 Italy
      • 7.3.2.5 Spain
      • 7.2.3.6 Rest Of Europe
    • 7.3.3 Asia-Pacific
      • 7.3.3.1china
      • 7.3.3.2 Japan
      • 7.3.3.3 India
      • 7.3.3.4 Australia & New Zealand
      • 7.3.3.5 South Korea
      • 7.3.3.6 Rest Of Asia-Pacific
    • 7.3.4 Middle East And Africa
      • 7.3.4.1 GCC
      • 7.3.4.2 South Africa
      • 7.3.4.3 Rest Of Middle East And Africa
    • 7.3.5 South America
      • 7.3.5.1 Brazil
      • 7.3.5.2 Argentina
      • 7.3.5.3 Rest Of South America

8 Competitive Landscape

  • 8.1 Mergers And Acquisition Analysis
  • 8.2 Agreements, Collaborations & Partnerships
  • 8.3 New Products Launches

9 Key Players

  • 9.1 Medtronic Plc
  • 9.2 Ge Healthcare
  • 9.3 Lantheus Medical Imaging Inc
  • 9.4 Hologic Inc
  • 9.5 Cardinal Health Inc
  • 9.6 Bayer Healthcare Ag
  • 9.7 Bracco Imaging Spa
  • 9.8 NTP Radioisotopes Soc Ltd
  • 9.9 Positron Corporation
  • 9.10 Siemens Healthcare
  • 9.11 Others

10 Future Of The Market

Back to Top